• Alda 1: ALDH2 Activator Workflows for Cardiac and Dermatitis

  2026-05-26

  Alda 1 enables targeted activation of ALDH2, offering double-digit fold enzymatic enhancement even in impaired variants. This article translates the latest mechanistic breakthroughs into actionable protocols for advancing cardiac ischemia and radiation dermatitis research.

• Digestive Transformations of Withania somnifera Bioactives M

  2026-05-25

  This study provides a detailed LC-MS/MS-based analysis of how key Withania somnifera (ashwagandha) bioactives are transformed under simulated digestive conditions, highlighting compound-specific stability and metabolic lability. The findings refine in vitro modeling of botanical pharmacokinetics and inform future preclinical research on complex herbal extracts.

• Bacterial Effector NleE Disrupts ZPR1 Phase Separation to In

  2026-05-25

  Ouyang et al. (2023) uncover a mechanism by which the EPEC effector NleE disrupts the liquid-liquid phase separation (LLPS) of the host zinc finger protein ZPR1, thereby antagonizing the unfolded protein response of the endoplasmic reticulum (UPRER). This work highlights the value of chemical crosslinkers for studying transient protein interactions and provides a foundation for future research on host-pathogen interactions and transcriptional regulation.

• Prevotella copri Depletes IPyA to Accelerate Breast Cancer P

  2026-05-24

  A recent study demonstrates that Prevotella copri, enriched in the gut microbiota of breast cancer patients, accelerates tumor growth by depleting host indole-3-pyruvic acid (IPyA) and inactivating AMPK via UHRF1-mediated mechanisms. These findings clarify a direct microbiota-metabolite-tumor axis and suggest new avenues for targeting breast cancer progression.

• Optimizing mRNA Workflows: Scenario-Driven Guidance with Pse

  2026-05-23

  This article delivers an evidence-based, scenario-driven guide for biomedical researchers seeking to enhance mRNA synthesis, cell assay reproducibility, and immunogenicity profiles using Pseudo-UTP (SKU B7972). Drawing from recent literature and emphasizing real laboratory challenges, we examine how Pseudo-UTP addresses RNA stability, translation efficiency, and product reliability. Practical protocol parameters and vendor selection insights empower bench scientists to make informed, workflow-optimized decisions.

• Applied Workflows with mCherry mRNA: Enhanced Red Fluorescen

  2026-05-22

  EZ Cap™ mCherry mRNA (5mCTP, ψUTP) empowers researchers with robust, immune-evasive red fluorescent protein expression for high-precision live-cell tracking and quantitative reporter assays. Its Cap 1 structure and nucleotide modifications enable reproducible results even in sensitive or immune-competent cell systems. Explore actionable workflows, troubleshooting, and the latest comparative insights for optimal deployment.

• Digestive Metabolomics of Ashwagandha: LC-MS/MS Reveals Key

  2026-05-22

  This study applies advanced LC-MS/MS and metabolomics to map how Withania somnifera (ashwagandha) extracts are chemically transformed under simulated digestive conditions. The research clarifies the stability and biotransformation of major withanolides, informing the development of more predictive in vitro models for botanical pharmacokinetics.

• Cy5 TSA Fluorescence System Kit: Amplify Sensitivity in IHC

  2026-05-21

  The Cy5 TSA Fluorescence System Kit empowers researchers to detect low-abundance targets in immunohistochemistry, immunocytochemistry, and in situ hybridization with up to 100-fold signal amplification. Its rapid, HRP-catalyzed workflow ensures reproducible, high-resolution imaging—enabling breakthrough insights in cancer and cellular biology.

• Z-WEHD-FMK: Illuminating Caspase-1/4/5 Pathways in Pyroptosi

  2026-05-21

  Explore how Z-WEHD-FMK empowers advanced inflammation research by irreversibly inhibiting caspase-1, -4, and -5. This article uniquely bridges molecular assay design with the latest mechanistic insights from HOXC8-caspase regulation, offering next-level guidance for cell biology and infectious disease research.

• Cabozantinib XL184 in RCC: Protocols, Adaptation, and Troubl

  2026-05-20

  Cabozantinib (XL184) enables precise multi-kinase pathway inhibition and phosphoproteomic adaptation analysis in renal cell carcinoma research. This article delivers actionable protocol guidance, troubleshooting strategies, and insights from chronic exposure models, positioning APExBIO’s reagent as a benchmark for reproducible antiangiogenic studies.

• JHU-083: A 6-diazo-5-oxo-L-norleucine Precursor for Glutamin

  2026-05-20

  JHU-083, a 6-diazo-5-oxo-L-norleucine precursor, is a potent and selective glutaminase antagonist with demonstrated utility in glutaminase pathway and neurological disease research. Its specificity for cerebral CD11b cells and robust solubility profile make it a high-value tool for experimental cerebral malaria and glutamate excitotoxicity models. Stringent purity and validated benchmarks support its role in advanced biochemical workflows.

• Actinomycin D: Precision Transcriptional Inhibition in Cance

  2026-05-19

  Actinomycin D (ActD) from APExBIO empowers researchers to dissect RNA stability, transcriptional stress, and apoptosis induction in advanced cancer models. This guide delivers actionable protocols, troubleshooting tips, and cross-study insights for maximizing experimental reliability and translational relevance.

• PD 173074: Precision FGFR/VEGFR2 Inhibition in Cancer Resear

  2026-05-19

  PD 173074 stands out as a nanomolar-potent, highly selective FGFR1 and VEGFR2 inhibitor, unlocking robust workflows for dissecting angiogenesis and tumor progression. This guide details experimental setups, advanced troubleshooting, and actionable insights from recent epigenetic research, making PD-173074 from APExBIO the go-to tool for targeted pathway inhibition.

• BRCA1/BARD1–pre-rRNA Interaction Facilitates DNA Repair via

  2026-05-18

  This study demonstrates that the BRCA1/BARD1 complex directly recognizes pre-ribosomal RNA, enabling its recruitment to DNA double-strand breaks and promoting homologous recombination. The findings reveal a previously unappreciated RNA-dependent mechanism for DNA repair, with implications for understanding cancer susceptibility and refining transcriptional regulation assays.

• FXR-KLF11 Axis: CDCA Suppresses JAK2/STAT3 in AKI Models

  2026-05-18

  This study demonstrates that Chenodeoxycholic Acid (CDCA) confers renal protection in contrast-induced acute kidney injury (CI-AKI) by activating FXR, which upregulates KLF11 and suppresses the JAK2/STAT3 pathway. The findings establish the FXR-KLF11 axis as a mechanistic target for future interventions in AKI and nuclear receptor signaling research.

404 records 7/27 page Previous Next First page 上5页 678910 下5页 Last page